Comments on methodological problems related to the use of biomarkers in clinical practice and research;Commentaires sur quelques problèmes méthodologiques liés à l'utilisation des biomarqueurs biologiques dans la recherche et la pratique cliniques

Annales Francaises d'Anesthesie et de Reanimation

Volumn 28, Issue 5, 2009, Pages 473-481

  Longrois, D ^a   Agavriloaia, M ^a   Devaux, Y ^b   Mertes, P M ^c,d  

^a Section of Radiology   (France)

^b LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^c INSERM   (France)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Biomarkers; Clinical reasoning; Methodology

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; NATRIURETIC PEPTIDE RECEPTOR C; NATRIURETIC PEPTIDE TYPE C;

ARTICLE; CLINICAL PRACTICE; CLINICAL RESEARCH; CONCEPTUAL FRAMEWORK; DISEASE MARKER; HEART INFARCTION; PUBLICATION; ROC CURVE;

ANIMALS; BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; DATA INTERPRETATION, STATISTICAL; HUMANS; RESEARCH;

EID: 67349149363     PISSN: 07507658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annfar.2009.02.042     Document Type: Article

References (36)

1. Baker M. In biomarkers we trust?. Nat Biotechnol 23 (2005) 297-304
2. Verdier B., Chauvet J.L., Tamion F., Cauliez B., Lavoinne A., Veber B., et al. Évaluation du NT-proBNP comme marqueur biologique de la dysfonction cardiaque du choc septique. Ann Fr Anesth Reanim 27 (2008) 135-140
3. Biomarkers definition working group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
4. Lassere M.N., Johnson K.R., Boers M., Tugwell P., Brooks P., Simon L., et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol 34 (2007) 607-615
5. Bassuk S.S., Rifai N., and Ridker P.M. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 29 (2004) 439-493
6. Ridker P.M., Buring J.E., Cook N.R., and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107 (2003) 391-397
7. Ridker P.M. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 92 (2003) 17K-22K
8. Scirica B.M., Morrow D.A., Cannon C.P., de Lemos J.A., Murphy S., Sabatine M.S., et al. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem 53 (2007) 1800-1807
9. de Bold A.J., Borenstein H.B., Veress A.T., and Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 28 (1981) 89-94
10. Sudoh T., Kangawa K., Minamino N., and Matsuo H. A new natriuretic peptide in porcine brain. Nature 332 (1988) 78-81
11. Sudoh T., Minamino N., Kangawa K., and Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 168 (1990) 863-870
12. Schweitz H., Vigne P., Moinier D., Frelin C., and Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem 267 (1992) 13928-13932
13. Daniels L.B., and Maisel A.S. Natriuretic peptides. J Am Coll Cardiol 50 (2007) 2357-2368
14. de Lemos J.A., McGuire D.K., and Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 362 (2003) 316-322
15. Mueller C., Breidthardt T., Laule-Kilian K., Christ M., and Perruchoud A.P. The integration of BNP and NT-proBNP into clinical medicine. Swiss Med Wkly 137 (2007) 4-12
16. Apple F.S., Wu A.H., Jaffe A.S., Panteghini M., and Christenson R.H. National academy of clinical biochemistry and ifcc committee for standardization of markers of cardiac damage laboratory medicine practice guidelines: analytical issues for biomarkers of heart failure. Clin Biochem 41 (2008) 222-226
17. Wagner D.R., Delagardelle C., Ernens I., Rouy D., Vaillant M., and Beissel J. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail 12 (2006) 66-72
18. Rouy D., Ernens I., Jeanty C., and Wagner D.R. Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation. Anal Biochem 338 (2005) 294-298
19. Apple F.S., Jesse R.L., Newby L.K., Wu A.H., and Christenson R.H. National academy of clinical biochemistry and ifcc committee for standardization of markers of cardiac damage laboratory medicine practice guidelines: analytical issues for biochemical markers of acute coronary syndromes. Circulation 115 (2007) e352-e355
20. Apple F.S., Wu A.H., Jaffe A.S., Panteghini M., Christenson R.H., Christenson R.H., et al. National academy of clinical biochemistry and ifcc committee for standardization of markers of cardiac damage laboratory medicine practice guidelines: analytical issues for biomarkers of heart failure. Clin Biochem 41 (2008) 222-226
21. Berroeta C., Provenchere S., Mongredien A., Lasocki S., Benessiano J., Dehoux M., et al. Dosage des isoformes cardiaques des troponines T ou I : intérêt en cardiologie et en anesthésie-réanimation. Ann Fr Anesth Reanim 25 (2006) 1053-1063
22. Apple F.S., Jesse R.L., Newby L.K., Wu A.H., Christenson R.H., Cannon C.P., et al. National academy of clinical biochemistry and ifcc committee for standardization of markers of cardiac damage laboratory medicine practice guidelines: analytical issues for biochemical markers of acute coronary syndromes. Clin Chem 53 (2007) 547-551
23. Christenson R.H., Duh S.H., Apple F.S., Bodor G.S., Bunk D.M., Panteghini M., et al. Toward standardization of cardiac troponin I measurements part II: assessing commutability of candidate reference materials and harmonization of cardiac troponin I assays. Clin Chem 52 (2006) 1685-1692
24. Morrow D.A., Cannon C.P., Jesse R.L., Newby L.K., Ravkilde J., Storrow A.B., et al. National academy of clinical biochemistry laboratory medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 115 (2007) e356-e375
25. Maisel A.S., Clopton P., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am Heart J 147 (2004) 1078-1084
26. Marie P.Y., Mertes P.M., Hassan-Sebbag N., de Talence N., Djaballah K., Djaballah W., et al. Exercise release of cardiac natriuretic peptides is markedly enhanced when patients with coronary artery disease are treated medically by beta-blockers. J Am Coll Cardiol 43 (2004) 353-359
27. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon III R.O., Criqui M., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
28. Ridker P.M., and Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 109 (2004) 1955-1959
29. Woloshin S., and Schwartz L.M. Distribution of C-reactive protein values in the United States. N Engl J Med 352 (2005) 1611-1613
30. Pearson T.A., Bazzarre T.L., Daniels S.R., Fair J.M., Fortmann S.P., Franklin B.A., et al. American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. Circulation 107 (2003) 645-651
31. Wu A.H., Jaffe A.S., Apple F.S., Jesse R.L., Francis G.L., Morrow D.A., et al. National academy of clinical biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem 53 (2007) 2086-2096
32. Le Manach Y., Perel A., Coriat P., Godet G., Bertrand M., and Riou B. Early and delayed myocardial infarction after abdominal aortic surgery. Anesthesiology 102 (2005) 885-891
33. Sabatine M.S., Morrow D.A., Jablonski K.A., Rice M.M., Warnica J.W., Domanski M.J., et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 115 (2007) 1528-1536
34. Zieske A.W., Tracy R.P., McMahan C.A., Herderick E.E., Homma S., Malcom G.T., et al. Elevated serum C-reactive protein levels and advanced atherosclerosis in youth. Arterioscler Thromb Vasc Biol 25 (2005) 1237-1243
35. Pepe M.S., Janes H., Longton G., Leisenring W., and Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 159 (2004) 882-890
36. Meigs J.B., Shrader P., Sullivan L.M., McAteer J.B., Fox C.S., Dupuis J., et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 20 (2008) 2208-2219